NCT02943668View on ClinicalTrials.gov

Deferasirox in Treating Patients With Very Low, Low, or Intermediate-Risk Red Blood Cell Transfusion Dependent Anemia or Myelodysplastic Syndrome

PHASE2TerminatedINTERVENTIONAL

Enrollment

2

Participants

Timeline

Start Date

March 2, 2017

Primary Completion Date

December 17, 2018

Study Completion Date

December 17, 2018

Conditions

AnemiaMyelodysplastic Syndrome

Interventions

DRUG

Deferasirox

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (1)

98109

Fred Hutch/University of Washington Cancer Consortium, Seattle

Sponsors

Collaborators (1)

Novartis Pharmaceuticals

All Listed Sponsors

collaborator

National Cancer Institute (NCI)

NIH

collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

Fred Hutchinson Cancer Center

OTHER